You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Discontinued ProductL-Homocysteinesulfinic acid (Cat. No. 0153) has been withdrawn from sale for commercial reasons.
Biological Activity for L-Homocysteinesulfinic acid
Transmitter candidate. Agonist at mGlu1α and mGlu5a subtypes expressed in clonal RGT cell lines.
Technical Data for L-Homocysteinesulfinic acid
|Storage||Desiccate at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Product Datasheets for L-Homocysteinesulfinic acid
References for L-Homocysteinesulfinic acid
References are publications that support the biological activity of the product.
Gorman and Griffiths (1994) Sulphur-containing excitatory amino acid-stimulated inositol phosphate formation in primary cultures of cerebellar granule cells is mediated predominately by N-MthD.-aspartate receptors. Neuroscience 59 299 PMID: 8008194
Kingston et al (1998) Sulphur-containing amino acids are agonists for group 1 metabotropic receptors expressed in clonal RGT cell lines. Neuropharmacology 37 277 PMID: 9681926
Mewett et al (1983) Pharmacology of the excitatory actions of sulphonic and sulphinic amino acids. CNS Receptors: From Molecular Pharmacology to Beha 163-174
View Related Products by Target
Keywords: L-Homocysteinesulfinic acid, L-Homocysteinesulfinic acid supplier, Glutamate, (Metabotropic), Group, I, Receptors, 0153, Tocris Bioscience
Citations for L-Homocysteinesulfinic acid
Citations are publications that use Tocris products.
Currently there are no citations for L-Homocysteinesulfinic acid.
Reviews for L-Homocysteinesulfinic acid
There are currently no reviews for this product. Be the first to review L-Homocysteinesulfinic acid and earn rewards!
Have you used L-Homocysteinesulfinic acid?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Huntington's Disease Poster
Huntington's disease (HD) is a severe monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the effects of mutant huntingtin aggregation implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.
Learning & Memory Poster
Recognition memory enables us to make judgements about whether or not we have encountered a particular stimulus before. This poster outlines the cellular mechanisms underlying recognition memory and its links to long-term depression, as well as the use of pharmacological intervention to assess the role of neurotransmitters in recognition memory.
Parkinson's Disease Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.